LFWD

Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia ReWalk was use d for a median of 33 months, with no reported falls or exoskeleton-related fractures during the observation period ; participants maintain ed 3,000 + steps per month, demonstrating sustained real-world utilization Participants reported high satisfaction including improvements in quality of life, mental health, bowel and bladder management , as well as less pain Long-term real-world evidence adds to the growing body of data supporting broader access, reimbursement and adoption of ReWalk HUDSON, Mass. and YOKNEAM ILLIT, Israel and BERLIN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept.

Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy

Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to a loss of $6.96 per share a year ago.

Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call.

Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate growth, expand patient access and improve commercial scalability HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones

Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic disease